Jointly provided by A. Webb Roberts Center for CME of Baylor Scott & White Health and MedNet
Supported by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
This webcast is intended to improve care of patients with type 2 diabetes mellitus by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This webcast is designed to meet the educational needs of diabetologists, family medicine physicians, endocrinologists, primary care physicians, managed care specialists, and other health care professionals who diagnose, treat, and manage patients with type 2 diabetes mellitus.
As a result of participating in the activity, learners should be better able to:
Compare different GLP-1 receptor agonists on glycemic control (HbA1c, postprandial glucose and fasting plasma glucose) in type 2 diabetes mellitus (T2DM)
Compare different GLP-1 receptor agonists on glycemic control (daily vs weekly administration), weight control, weigh reduction and cardiovascular effects in T2DM
Outline the role of SGLT-2 Inhibitors in achieving individualized HbA1c goals and reducing the risk of complications
Identify the role of new and emerging insulin formulations in the treatment of diabetes
Conflict Of Interest Disclosure Policy
It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.
Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.
Guillermo E. Umpierrez, MD Professor of Medicine Emory University School of Medicine Director Diabetes & Endocrinology Section Grady Health System Atlanta, GA
Dr. Umpierrez discloses that he is a Consultant/Advisory Board member for Merck Sharp and Dohme, and Sanofi; received Research Funding from Merck, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Sanofi; and has Equity, Stock, or Options in Biomedical Industry Companies or Publishers from BMJ Open Diabetes Research & Care, Endocrine Society, ADA, and AACE.
Bruce W. Bode, MD Atlanta Diabetes Associates Associate Professor of Medicine Emory University School of Medicine Atlanta, GA
Dr. Bode discloses that he is a Consultant for AstraZeneca, Janssen, Medtronic, Novo Nordisk, and Sanofi; on the Speaker’s Bureau of AstraZeneca, BI/Lilly, Janssen, Medtronic, Novo Nordisk, and Sanofi; received Research and Grant Support to Employer from Abbott, AstraZeneca, BI/Lilly, DexCom, Diasome, GSK, Janssen, Lexicon, Medtronic, Novo Nordisk, Pfizer, Sanofi, and Sensonics; and has Stock options from Aseko.
Jaime A. Davidson, MD Professor of Medicine Division of Endocrinology Diabetes and Metabolism Touchstone Diabetes Center The University of Texas South Western Medical Center Dallas, TX
Dr. Davidson discloses that he is a Consultant/Advisory Board member for Amgen, AstraZeneca, Janssen, GlaxoSmithKline, Remd Bio, Bristol-Myers Squibb, Merck Sharp and Dohme, Novo Nordisk, Lifescan, Lilly USA, LLC, Aspire Bariatrics, and Sanofi; and is on the Speaker’s Bureau of AstraZeneca, Janssen, Novo Nordisk, and Takeda.
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
Guillermo E. Umpierrez, MD, discloses that he is a Consultant/Advisory Board member for Merck Sharp and Dohme and Sanofi; received Research Funding from Merck, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Sanofi; and has Equity, Stock, or Options in Biomedical Industry Companies or Publishers from BMJ Open Diabetes Research & Care, Endocrine Society, ADA, and AACE.
Kamatham A. Naidu, PhD (MedNet, LLC), has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and MedNet. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.
The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.
The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
NON-ENDORSEMENT OF PRODUCTS The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
There are no fees for participating in or receiving credit for this webcast. During the period May 12, 2017 through May 12, 2018, participants must read all of the material and study the educational webcast.
This webcast includes text, graphics, and may include multimedia features.
To obtain credit, a score of 75% or above on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the CME Provider at 214-820-2317.
A. Webb Roberts Center for CME of Baylor Scott & White Health observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.